Dr. Yelena Janjigian on the MATTERHORN Study: Durvalumab Plus FLOT in Gastric Cancer at ASCO GI 2024
By Yelena Janjigian, MD - Last Updated: March 19, 2025At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Dr. Yelena Janjigian discussed the results of the phase 3 MATTERHORN study, which analyzed pCR to FLOT with or without durvalumab in patients with resectable gastric and gastroesophageal junction cancers.
Catch up on more ASCO GI 2024 coverage here.
Advertisement
Advertisement
Related Posts
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Meta-analysis data has shown that HAIP combined with systemic chemotherapy can provide a pooled 3-year OS rate of 39.5%.
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
Dr. Ethan Ludmir discusses the phase II EXTEND trial on MDT with systemic therapy for pancreatic ductal adenocarcinoma.
Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.